Persistence and compliance with medication management in the treatment of overactive bladder.
Overactive bladder (OAB) is a common and chronic condition that impacts patients' daily activities and quality of life. Pharmaco-therapy for OAB is a mainstay of treatment. Antimuscarinics and β3-adrenoceptor agonists are the two major classes of oral pharmacotherapy and have similar efficacy for treating the symptoms of OAB. Owing to the chronic nature of OAB, long-term use of medication is essential for OAB symptom control and positive health outcomes. However, many patients elect to stop their medications during the treatment period. Unmet expectations of treatment and side effects seem to be the major factors for discontinuing OAB pharmacotherapy. Furthermore, the short- and long-term persistence and compliance with medication management are markedly worse in OAB than in other chronic medical conditions. Improvement in persistence and compliance with OAB pharmacotherapy is a hot topic in OAB treatment and should be an important goal in the treatment of OAB. Effective strategies should be identified to improve persistence and compliance. In this review, we outline what is known about persistence and compliance and the factors affecting persistence with pharmacotherapy in patients with OAB.
['Kim|Tae Heon|TH|', 'Lee|Kyu-Sung|KS|']
D058667:Adrenergic beta-3 Receptor Agonists D006801:Humans D055118:Medication Adherence D018727:Muscarinic Antagonists D009626:Terminology as Topic D053201:Urinary Bladder, Overactive D064804:Urological Agents
Compliance Medication adherence Mirabegron Muscarinic antagonists Overactive urinary bladder